Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-III

Model scores of the 29,894 trials active now.

Model score 15% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (381 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-02-09. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: ischemicmristrokethe patientct
  Phrases that lowered it: open labelm2kgrandomized openeffect
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 48 (lowers risk) · Sponsor's track record
• Phase: 3 (lowers risk) · Design
• Drug's FAERS reports with a death: 9.7% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, neurology: Yes (raises risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Blinding: single (lowers risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Drug's FAERS reports marked serious: 74.4% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 28 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Endovascular Treatment With or Without Preceding Intravenous Tenecteplase (TNK) in Patients With Late-window acUte Ischemic Stroke Due to Middle Cerebral Artery Occlusion NCT06221371 · started 2024 · scored riskier than 56% of active trials completed
• CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase II NCT04516993 · started 2021 · scored riskier than 19% of active trials completed
• Tenecteplase in Stroke Patients Between 4.5 and 24 Hours NCT03785678 · started 2019 · scored riskier than 94% of active trials completed
• Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients with Large Vessel Occlusion NCT04454788 · started 2020 · scored riskier than 86% of active trials terminated
• Determining the Optimal Dose of Tenecteplase Before Endovascular Therapy for Ischaemic Stroke (EXTEND-IA TNK Part 2) NCT03340493 · started 2017 · scored riskier than 96% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.